Nivolumab Trial
Phase 2
40
about 13 years
12+
1 site in MD
What this study is about
Researchers are testing if Nivolumab can slow the growth of certain cancers, specifically Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders and EBV-positive non-Hodgkin lymphomas. The trial will evaluate the safety of this treatment in adults and children with these conditions who have not responded to other therapies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Nivolumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion
Primary: overall response rate of nivolumab in patients with EBV-positive LPD and EBV-positive NHL
Secondary: PFS of patients with EBV-LPD treated with nivolumab, overall survival of patients with EBV-LPD treated with nivolumab, toxicity profile of nivolumab in patients with EBV-LPD
Oncology